Your browser is no longer supported. Please, upgrade your browser.
Settings
LOXO Loxo Oncology, Inc. daily Stock Chart
LOXO [NASD]
Loxo Oncology, Inc.
Index- P/E- EPS (ttm)-4.41 Insider Own1.10% Shs Outstand29.54M Perf Week-2.78%
Market Cap4.90B Forward P/E- EPS next Y-3.15 Insider Trans-85.75% Shs Float27.99M Perf Month24.65%
Income-127.90M PEG- EPS next Q-0.75 Inst Own- Short Float12.89% Perf Quarter47.11%
Sales59.70M P/S81.99 EPS this Y-53.30% Inst Trans-1.21% Short Ratio7.91 Perf Half Y119.08%
Book/sh12.80 P/B12.95 EPS next Y-94.40% ROA-21.20% Target Price140.57 Perf Year248.86%
Cash/sh24.04 P/C6.89 EPS next 5Y- ROE-31.60% 52W Range44.05 - 175.99 Perf YTD96.85%
Dividend- P/FCF20.16 EPS past 5Y- ROI-40.30% 52W High-5.84% Beta2.42
Dividend %- Quick Ratio3.50 Sales past 5Y- Gross Margin- 52W Low276.19% ATR7.18
Employees30 Current Ratio3.50 Sales Q/Q- Oper. Margin- RSI (14)71.94 Volatility3.75% 4.78%
OptionableYes Debt/Eq0.00 EPS Q/Q87.60% Profit Margin- Rel Volume0.63 Prev Close167.52
ShortableYes LT Debt/Eq0.00 EarningsMay 08 BMO Payout- Avg Volume455.76K Price165.71
Recom1.30 SMA2017.76% SMA5027.74% SMA20066.59% Volume285,330 Change-1.08%
May-17-18Reiterated Stifel Buy $145 → $190
Apr-16-18Upgrade Morgan Stanley Equal-Weight → Overweight
Mar-21-18Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-22-18Initiated Oppenheimer Outperform $132
Nov-28-17Initiated William Blair Outperform
Aug-29-17Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-05-17Upgrade Citigroup Neutral → Buy
Jun-05-17Reiterated Stifel Buy $52 → $71
Apr-03-17Initiated Morgan Stanley Overweight $59
Mar-10-17Downgrade Citigroup Buy → Neutral
Feb-08-17Initiated Jefferies Buy $50
Mar-16-16Reiterated Stifel Buy $37 → $36
Jan-15-16Initiated Citigroup Buy $32
Nov-11-15Reiterated Stifel Buy $26 → $37
Sep-02-14Initiated Stifel Buy $20
Sep-02-14Initiated Oppenheimer Outperform $20
May-19-18 09:32AM  Does a Blue Ribbon Make This Biotech Stock a Buy Now? Motley Fool
May-18-18 04:51PM  Winners and Losers From the Biggest Cancer Meeting of the Year (So Far) Motley Fool
10:16AM  This Tiny Cancer Drug Upstart Just Got Even More Interesting Motley Fool
08:10AM  Todays Research Reports on Stocks to Watch: Loxo Oncology and Jounce Therapeutics ACCESSWIRE
May-17-18 01:52PM  Here's Why Loxo Oncology Rose as Much as 23.3% Today Motley Fool +20.09%
10:39AM  Loxo Oncology shares surge 21% on preview of cancer drug trial data MarketWatch
09:31AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
09:19AM  UPDATE 1-Loxo Oncology's targeted RET drug shows promise in early trial Reuters
07:15AM  Dow Jones Futures Today: These 2 Tech Stocks Near Buys Move On Earnings; This Biotech Soars Investor's Business Daily
May-16-18 05:38PM  After-hours buzz: CSCO, JACK & more CNBC
05:18PM  Loxo Oncology's targeted RET drug shows promise in early trial Reuters
05:00PM  Loxo Oncology Announces Details of LOXO-292 Clinical Data Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-15-18 03:52PM  Edited Transcript of LOXO earnings conference call or presentation 8-May-18 12:00pm GMT Thomson Reuters StreetEvents
May-08-18 06:45AM  Loxo Oncology Reports First Quarter 2018 Financial Results GlobeNewswire
May-07-18 04:30PM  Loxo Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-01-18 06:45AM  Loxo Oncology to Announce First Quarter 2018 Financial Results GlobeNewswire
Apr-24-18 08:27AM  How Blueprint Medicines Got The Blues Forbes
Apr-17-18 11:41AM  Loxo Oncology (LOXO) Shares March Higher, Can It Continue? Zacks
08:10AM  Todays Research Reports on Stocks to Watch: Clovis Oncology and Loxo Oncology ACCESSWIRE
Apr-16-18 09:52AM  Morgan Stanley Upgrades Loxo On The Potential Of A Targeted Cancer Therapy Benzinga +8.50%
Apr-12-18 07:45AM  Investor Expectations to Drive Momentum within Loxo Oncology, Kinross Gold, Marlin Business Services, lululemon athletica inc, LG Display Co., and QIWI Discovering Underlying Factors of Influence GlobeNewswire
Apr-10-18 08:06AM  Loxo, Illumina to partner for diagnostic tool targeting cancer Reuters +8.21%
07:44AM  Loxo and Illumina in partnership over diagnostic for cancer drug Reuters
06:45AM  Loxo Oncology and Illumina to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics GlobeNewswire
06:45AM  Illumina and Loxo Oncology to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics Business Wire
Apr-05-18 08:00AM  Todays Research Reports on Stocks to Watch: Loxo Oncology and Boston Scientific ACCESSWIRE -7.63%
Apr-04-18 06:45AM  Loxo Oncology Announces Acceptance of LOXO-292 Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire +10.09%
Apr-03-18 07:22AM  High-flying biotech Loxo tempers bullish view for cancer drug Reuters
07:00AM  FOCUS-High-flying biotech Loxo tempers bullish view for cancer drug Reuters
Mar-28-18 07:10AM  Blog Exposure - Loxo Oncology Completed Rolling Submission of NDA to the FDA for Larotrectinib for TRK Fusion Cancer Treatment ACCESSWIRE
Mar-26-18 06:45AM  Loxo Oncology Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion Cancer GlobeNewswire +5.47%
06:45AM  Bayer Announces Completion of Rolling Submission of New Drug Application in the U.S. for Larotrectinib for the Treatment of TRK Fusion Cancer PR Newswire
Mar-21-18 11:59AM  Turning Neutral: Morgan Stanley Downgrades Sarepta, Loxo Oncology, Global Blood Therapeutics Benzinga
08:30AM  Todays Research Reports on Trending Tickers: AnaptysBio and Loxo Oncology ACCESSWIRE
Mar-13-18 08:15AM  Report: Developing Opportunities within Lululemon Athletica Inc., Loxo Oncology, MakeMyTrip, Sumitomo Mitsui Financial Group, Seagate Technology, and New York Mortgage Trust Future Expectations, Projections Moving into 2018 GlobeNewswire
Mar-06-18 06:45AM  Loxo Oncology to Present at the Cowen and Company 38th Annual Health Care Conference GlobeNewswire
Mar-01-18 10:21PM  Edited Transcript of LOXO earnings conference call or presentation 1-Mar-18 1:00pm GMT Thomson Reuters StreetEvents
07:53AM  Loxo reports 4Q loss Associated Press
06:45AM  Loxo Oncology Reports Fourth Quarter and Year-End 2017 Financial Results GlobeNewswire
06:15AM  Loxo Oncology Inc to Host Earnings Call ACCESSWIRE
Feb-28-18 06:35AM  Should You Buy Loxo Oncology (LOXO) Ahead of Earnings? Zacks
Feb-22-18 08:10AM  Todays Research Reports on Stocks to Watch: Halozyme Therapeutics and Loxo Oncology ACCESSWIRE
06:45AM  Loxo Oncology to Announce Fourth Quarter and Year-End 2017 Financial Results GlobeNewswire
Feb-21-18 05:00PM  Loxo Oncology Announces Publication of Larotrectinib Clinical Data in The New England Journal of Medicine GlobeNewswire
05:00PM  Bayer Announces Publication of Larotrectinib Data in The New England Journal of Medicine PR Newswire
Jan-25-18 09:02AM  Taking Stock of Arrowhead Pharmaceuticals Financial Performance Market Realist
07:32AM  What Led to Arrowhead Pharmaceuticals Revenue Surge in 2017? Market Realist
Jan-24-18 01:30PM  Arrowheads Candidates for Hepatitis B, Cardiovascular Diseases Market Realist
12:00PM  Taking a Closer Look at Arrowhead Pharmaceuticals TRIM Platform Market Realist
10:25AM  Analysts Recommendations for Arrowhead and Its Peers Market Realist
Jan-15-18 08:07AM  See what the IHS Markit Score report has to say about Loxo Oncology Inc. Markit
Jan-10-18 07:37AM  Inside Ignytas Financial Performance Market Realist
Jan-09-18 02:15PM  A Close Look at Ignytas Licensing Agreement Market Realist
12:41PM  Analyst Recommendations for Ignyta and Its Peers in January 2018 Market Realist
Jan-02-18 08:05AM  See what the IHS Markit Score report has to say about Loxo Oncology Inc. Markit
Dec-22-17 04:13PM  Christmas Comes Early For These 5 Biotechnology Stocks Investor's Business Daily
02:00PM  Roche Jumps Into Mergers and Acquisitions With $1.7 Billion Deal Motley Fool
Dec-20-17 06:46AM  Bayer Announces that Loxo Oncology, Inc., Initiates Rolling NDA Submission for Larotrectinib for the Treatment of TRK Fusion Cancers PR Newswire
06:45AM  Loxo Oncology Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion Cancers GlobeNewswire
Dec-04-17 06:48AM  Updated larotrectinib pediatric Phase I clinical trial data demonstrates response in TRK fusion cancers PR Newswire
06:45AM  Loxo Oncology Announces Updated Larotrectinib Pediatric Clinical Trial Data Demonstrating Continued Durability of Response in TRK Fusion Cancers GlobeNewswire
Nov-30-17 03:42PM  Loxo Oncology, Inc. Fundamental Analysis : November 30, 2017 Capital Cube
08:05AM  See what the IHS Markit Score report has to say about Loxo Oncology Inc. Markit
Nov-21-17 07:10PM  Cramer's lightning round: Don't sell Deutsche Bank. It's ... CNBC Videos
06:01AM  Fighting Cancer One Patient At A Time Forbes
Nov-19-17 11:43AM  3 Biotech Stocks to Be Thankful for This Year Motley Fool
Nov-18-17 12:35PM  Is Loxo Oncology's Deal With Bayer Bad News? Motley Fool
Nov-16-17 07:13AM  Pharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with Loxo Zacks
07:10AM  Corporate News Blog - Loxo Oncology Collaborates with Bayer to Develop and Commercialize Larotrectinib and LOXO-195 ACCESSWIRE
Nov-15-17 08:16AM  Biotech Stock Roundup: Dynavax Vaccine Gets FDA Nod, Loxo Inks Deal with Bayer Zacks
08:07AM  See what the IHS Markit Score report has to say about Loxo Oncology Inc. Markit
Nov-14-17 04:18PM  Biotechs Sell Off In Droves Are Investors Seeking Mergers? Investor's Business Daily
04:13PM  This Cancer Biotech Is Falling On Its $1.55 Billion Bayer Deal Investor's Business Daily
03:30PM  Bayer Bets Big on a Tiny Cancer Drug Up-and-Comer Motley Fool
02:12PM  Loxo's Good Deed Goes Punished Bloomberg
12:10PM  Loxo signs lucrative cancer drug deal with Bayer, but shares fall Reuters
09:29AM  What Is Loxo Oncology Incs (LOXO) Share Price Doing? Simply Wall St.
09:10AM  Loxo, Bayer to co-develop cancer drugs in up to $1.55 bln deal Reuters
08:03AM  Loxo Sells Bayer Rights To Rare Cancer Drug For More Than $1 Billion Forbes
07:45AM  Loxo announces $400 mln Bayer cancer partnership MarketWatch
07:21AM  Loxo Oncology to develop, commercialize cancer drugs with Bayer Reuters
07:00AM  Loxo Oncology Announces Global Development and Commercialization Partnership with Bayer for Larotrectinib and LOXO-195 GlobeNewswire
07:00AM  Bayer and Loxo Oncology to develop and commercialize two therapies that selectively target genetic drivers of cancer PR Newswire
Nov-10-17 08:04AM  See what the IHS Markit Score report has to say about Loxo Oncology Inc. Markit
Nov-07-17 08:36PM  Edited Transcript of LOXO earnings conference call or presentation 2-Nov-17 12:00pm GMT Thomson Reuters StreetEvents
06:45AM  Loxo Oncology to Present at Upcoming Investor Conferences GlobeNewswire
Nov-06-17 08:04AM  See what the IHS Markit Score report has to say about Loxo Oncology Inc. Markit
Nov-02-17 10:41AM  Loxo reports 3Q loss Associated Press
06:45AM  Loxo Oncology Announces Third Quarter 2017 Financial Results GlobeNewswire
06:00AM  Loxo Oncology Inc to Host Earnings Call ACCESSWIRE
Oct-27-17 08:06AM  See what the IHS Markit Score report has to say about Loxo Oncology Inc. Markit
Oct-26-17 06:45AM  Loxo Oncology to Announce Third Quarter 2017 Financial Results and Host Conference Call GlobeNewswire
Oct-18-17 06:00AM  Loxo Oncology Announces Positive Top-Line Results from Independent Review Committee Assessment of Larotrectinib Dataset GlobeNewswire
Oct-17-17 08:04AM  See what the IHS Markit Score report has to say about Loxo Oncology Inc. Markit
Oct-16-17 08:01AM  6 Top Biotech Companies In Innovation Earn Recognition In New Awards Investor's Business Daily
07:48AM  Loxo Oncology Fights Cancer With 'Tumor Agnostic' Approach Investor's Business Daily
07:47AM  Buying And Selling Stocks Right Are Keys To This Top Mutual Fund's Success Investor's Business Daily
Oct-12-17 08:05AM  See what the IHS Markit Score report has to say about Loxo Oncology Inc. Markit
Oct-09-17 08:05AM  See what the IHS Markit Score report has to say about Loxo Oncology Inc. Markit +7.24%
Oct-04-17 08:05AM  See what the IHS Markit Score report has to say about Loxo Oncology Inc. Markit
Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company's preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets; strategic partnership with Illumina, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and research collaboration agreement with Veracyte, Inc. to develop medicines for patients with genetically defined cancers. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bilenker Joshua H.President & CEOMay 15Option Exercise1.187,5008,880190,207May 16 04:44 PM
Van Naarden JacobChief Business OfficerMay 15Option Exercise3.651,5415,6221,541May 16 04:46 PM
Bilenker Joshua H.President & CEOMay 15Sale137.417,5001,030,575182,707May 16 04:44 PM
Van Naarden JacobChief Business OfficerMay 15Sale137.291,541211,5660May 16 04:46 PM
Bilenker Joshua H.President & CEOMay 14Option Exercise1.187,5008,880190,207May 16 04:44 PM
Van Naarden JacobChief Business OfficerMay 14Option Exercise3.651,5415,6221,541May 16 04:46 PM
Burstein JenniferSenior VP of FinanceMay 14Option Exercise11.351,70019,2951,700May 16 04:45 PM
Bilenker Joshua H.President & CEOMay 14Sale135.617,5001,017,071182,707May 16 04:44 PM
Van Naarden JacobChief Business OfficerMay 14Sale137.541,541211,9490May 16 04:46 PM
Burstein JenniferSenior VP of FinanceMay 14Sale136.931,700232,7840May 16 04:45 PM
Bilenker Joshua H.President & CEOApr 25Option Exercise1.187,5008,880190,207Apr 26 04:31 PM
Van Naarden JacobChief Business OfficerApr 25Option Exercise3.651,5415,6221,541Apr 26 04:32 PM
Bilenker Joshua H.President & CEOApr 25Sale130.867,500981,423182,707Apr 26 04:31 PM
Van Naarden JacobChief Business OfficerApr 25Sale130.801,541201,5630Apr 26 04:32 PM
Bilenker Joshua H.President & CEOApr 24Option Exercise1.187,5008,880190,207Apr 26 04:31 PM
Van Naarden JacobChief Business OfficerApr 24Option Exercise3.651,5415,6221,541Apr 26 04:32 PM
Burstein JenniferSenior VP of FinanceApr 24Option Exercise11.351,70019,2951,700Apr 26 04:33 PM
Bilenker Joshua H.President & CEOApr 24Sale131.397,500985,430182,707Apr 26 04:31 PM
Van Naarden JacobChief Business OfficerApr 24Sale131.671,541202,8980Apr 26 04:32 PM
Burstein JenniferSenior VP of FinanceApr 24Sale131.651,700223,8050Apr 26 04:33 PM
Kunkel Lori AnneDirectorApr 20Sale132.685,000663,3786,840Apr 24 04:30 PM
Bilenker Joshua H.President & CEOMar 14Option Exercise1.187,5008,880190,207Mar 15 05:00 PM
Van Naarden JacobChief Business OfficerMar 14Option Exercise3.651,5415,6221,541Mar 15 05:01 PM
Van Naarden JacobChief Business OfficerMar 14Sale131.461,541202,5800Mar 15 05:01 PM
Bilenker Joshua H.President & CEOMar 14Sale131.507,500986,215182,707Mar 15 05:00 PM
Bilenker Joshua H.President & CEOMar 13Option Exercise1.187,5008,880190,207Mar 15 05:00 PM
Van Naarden JacobChief Business OfficerMar 13Option Exercise3.651,5415,6221,541Mar 15 05:01 PM
Burstein JenniferSenior VP of FinanceMar 13Option Exercise11.351,70019,2951,700Mar 15 05:02 PM
Burstein JenniferSenior VP of FinanceMar 13Sale131.331,700223,2620Mar 15 05:02 PM
Van Naarden JacobChief Business OfficerMar 13Sale131.351,541202,4150Mar 15 05:01 PM
Bilenker Joshua H.President & CEOMar 13Sale131.587,500986,842182,707Mar 15 05:00 PM
Bilenker Joshua H.President & CEOFeb 13Option Exercise1.187,5008,880190,207Feb 14 05:36 PM
Van Naarden JacobChief Business OfficerFeb 13Option Exercise3.651,5415,6221,541Feb 14 05:35 PM
Van Naarden JacobChief Business OfficerFeb 13Sale99.241,541152,9340Feb 14 05:35 PM
Bilenker Joshua H.President & CEOFeb 13Sale99.757,500748,152182,707Feb 14 05:36 PM
Bilenker Joshua H.President & CEOFeb 12Option Exercise1.187,5008,880190,207Feb 14 05:36 PM
Van Naarden JacobChief Business OfficerFeb 12Option Exercise3.651,5415,6221,541Feb 14 05:35 PM
Burstein JenniferSenior VP of FinanceFeb 12Option Exercise11.351,70019,2951,700Feb 14 05:37 PM
Burstein JenniferSenior VP of FinanceFeb 12Sale93.241,700158,5040Feb 14 05:37 PM
Van Naarden JacobChief Business OfficerFeb 12Sale93.431,541143,9780Feb 14 05:35 PM
Bilenker Joshua H.President & CEOFeb 12Sale93.387,500700,377182,707Feb 14 05:36 PM
Naider Avi Z.DirectorJan 22Sale100.0015,0001,500,000126,118Jan 25 05:09 PM
Bilenker Joshua H.President & CEOJan 17Option Exercise1.187,5008,880190,207Jan 18 05:01 PM
Van Naarden JacobChief Business OfficerJan 17Option Exercise3.651,5415,6221,541Jan 18 05:02 PM
Van Naarden JacobChief Business OfficerJan 17Sale88.301,541136,0650Jan 18 05:02 PM
Bilenker Joshua H.President & CEOJan 17Sale88.487,500663,584182,707Jan 18 05:01 PM
Bilenker Joshua H.President & CEOJan 16Option Exercise1.187,5008,880190,207Jan 18 05:01 PM
Burstein JenniferSenior VP of FinanceJan 16Option Exercise11.351,50017,0251,500Jan 18 05:02 PM
Van Naarden JacobChief Business OfficerJan 16Option Exercise3.651,5415,6221,541Jan 18 05:02 PM
Van Naarden JacobChief Business OfficerJan 16Sale88.131,541135,8020Jan 18 05:02 PM
Burstein JenniferSenior VP of FinanceJan 16Sale87.501,500131,2430Jan 18 05:02 PM
Bilenker Joshua H.President & CEOJan 16Sale87.947,500659,515182,707Jan 18 05:01 PM
MAYLEBEN TIMOTHY MDirectorDec 20Sale80.4910,000804,9480Dec 22 04:14 PM
AISLING CAPITAL III LP10% OwnerDec 19Sale80.50250,00020,125,0003,438,920Dec 20 04:31 PM
Bilenker Joshua H.President & CEODec 15Option Exercise1.187,5008,880190,207Dec 18 05:40 PM
Van Naarden JacobChief Business OfficerDec 15Option Exercise3.651,5415,6221,541Dec 18 05:42 PM
Van Naarden JacobChief Business OfficerDec 15Sale79.121,541121,9210Dec 18 05:42 PM
Bilenker Joshua H.President & CEODec 15Sale78.907,500591,739182,707Dec 18 05:40 PM
Bilenker Joshua H.President & CEODec 14Option Exercise1.187,5008,880190,207Dec 18 05:40 PM
Van Naarden JacobChief Business OfficerDec 14Option Exercise3.651,5415,6221,541Dec 18 05:42 PM
Burstein JenniferVice President of FinanceDec 14Option Exercise11.351,70019,2951,700Dec 18 05:44 PM
Burstein JenniferVice President of FinanceDec 14Sale83.271,700141,5540Dec 18 05:44 PM
Van Naarden JacobChief Business OfficerDec 14Sale83.271,541128,3190Dec 18 05:42 PM
Bilenker Joshua H.President & CEODec 14Sale83.357,500625,120182,707Dec 18 05:40 PM
Bonita David PDirectorDec 08Sale82.50250,00020,625,000941,000Dec 12 02:06 PM
ORBIMED ADVISORS LLCDirectorDec 08Sale82.50250,00020,625,000941,000Dec 12 02:02 PM
Bilenker Joshua H.President & CEONov 28Option Exercise1.187,5008,880190,207Nov 29 05:17 PM
Van Naarden JacobChief Business OfficerNov 28Option Exercise3.651,5415,6221,541Nov 29 05:21 PM
Van Naarden JacobChief Business OfficerNov 28Sale74.161,541114,2820Nov 29 05:21 PM
Bilenker Joshua H.President & CEONov 28Sale74.227,500556,648182,707Nov 29 05:17 PM
Bilenker Joshua H.President & CEONov 27Option Exercise1.187,5008,880190,207Nov 29 05:17 PM
Van Naarden JacobChief Business OfficerNov 27Option Exercise3.651,5415,6221,541Nov 29 05:21 PM
Burstein JenniferVice President of FinanceNov 27Option Exercise11.351,70019,2951,700Nov 29 05:25 PM
Burstein JenniferVice President of FinanceNov 27Sale74.821,700127,1930Nov 29 05:25 PM
Van Naarden JacobChief Business OfficerNov 27Sale74.831,541115,3160Nov 29 05:21 PM
Bilenker Joshua H.President & CEONov 27Sale74.687,500560,100182,707Nov 29 05:17 PM
MAYLEBEN TIMOTHY MDirectorNov 22Option Exercise20.913,00062,73013,000Nov 27 04:56 PM
AISLING CAPITAL III LP10% OwnerNov 22Sale75.00500,00037,500,0003,688,920Nov 27 07:29 PM
MAYLEBEN TIMOTHY MDirectorNov 22Sale75.853,000227,56310,000Nov 27 04:56 PM
Bonita David PDirectorNov 22Sale75.00267,00020,025,0001,191,000Nov 27 03:36 PM
ORBIMED ADVISORS LLCDirectorNov 22Sale75.00267,00020,025,0001,191,000Nov 27 03:30 PM
Flaherty Keith T.DirectorNov 20Sale75.997,250550,9219,732Nov 22 05:05 PM
Bonita David PDirectorNov 16Sale74.26270,00020,051,3891,458,000Nov 20 07:36 PM
ORBIMED ADVISORS LLCDirectorNov 16Sale74.26270,00020,051,3891,458,000Nov 20 07:31 PM
Kunkel Lori AnneDirectorNov 02Sale84.915,000424,57011,840Nov 06 05:03 PM
Bilenker Joshua H.President & CEOOct 31Option Exercise1.187,5008,880196,207Nov 01 05:03 PM
Van Naarden JacobChief Business OfficerOct 31Option Exercise3.651,5415,6221,541Nov 01 05:06 PM
Bilenker Joshua H.President & CEOOct 31Sale86.497,500648,702188,707Nov 01 05:03 PM
Van Naarden JacobChief Business OfficerOct 31Sale86.521,541133,3210Nov 01 05:06 PM
Bilenker Joshua H.President & CEOOct 30Option Exercise1.187,5008,880196,207Nov 01 05:03 PM
Van Naarden JacobChief Business OfficerOct 30Option Exercise3.651,5415,6221,541Nov 01 05:06 PM
Burstein JenniferVice President of FinanceOct 30Option Exercise11.351,70019,2951,700Nov 01 05:08 PM
Burstein JenniferVice President of FinanceOct 30Sale87.191,700148,2190Nov 01 05:08 PM
Van Naarden JacobChief Business OfficerOct 30Sale87.261,541134,4680Nov 01 05:06 PM
Bilenker Joshua H.President & CEOOct 30Sale87.207,500653,967188,707Nov 01 05:03 PM
Naider Avi Z.DirectorOct 16Sale90.005,000450,000144,118Oct 18 05:03 PM
Bilenker Joshua H.President & CEOSep 19Option Exercise1.187,5008,880196,207Sep 20 05:04 PM
Van Naarden JacobChief Business OfficerSep 19Option Exercise3.651,5415,6221,541Sep 20 05:05 PM
Van Naarden JacobChief Business OfficerSep 19Sale88.791,541136,8270Sep 20 05:05 PM
Bilenker Joshua H.President & CEOSep 19Sale88.787,500665,870188,707Sep 20 05:04 PM